Cardio Diagnostics held its annual meeting on November 15, 2024, with 55.51% of eligible shares represented. Shareholders approved all four key proposals, including the election of seven directors and a significant reverse stock split authorization.Notably, stockholders approved an amendment allowing for a reverse stock split ratio between 1-for-5 and 1-for-40, to be implemented at the Board's discretion within one year. The meeting also approved the potential issuance of 20% or more of common stock in non-public transactions under Nasdaq Rule 5635(d), and ratified Prager Metis CPA's LLC as the independent auditor for FY2024.All seven director nominees were successfully elected, including Dr. Meeshanthini Dogan and Dr. Robert Philibert, with Paul F. Burton receiving the highest number of favorable votes at 7,466,218, while Dr. Warren Hosseinion received the most withheld votes at 1,885,711.

Cardio Diagnostics held its annual meeting on November 15, 2024, with 55.51% of eligible shares represented. Shareholders approved all four key proposals, including the election of seven directors and a significant reverse stock split authorization.Notably, stockholders approved an amendment allowing for a reverse stock split ratio between 1-for-5 and 1-for-40, to be implemented at the Board's discretion within one year. The meeting also approved the potential issuance of 20% or more of common stock in non-public transactions under Nasdaq Rule 5635(d), and ratified Prager Metis CPA's LLC as the independent auditor for FY2024.All seven director nominees were successfully elected, including Dr. Meeshanthini Dogan and Dr. Robert Philibert, with Paul F. Burton receiving the highest number of favorable votes at 7,466,218, while Dr. Warren Hosseinion received the most withheld votes at 1,885,711.